Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Paclitaxel (taxol)

D R Kohler1, B R Goldspiel

  • 1Department of Pharmacy, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892.

Pharmacotherapy
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Paclitaxel, a novel anticancer drug, stabilizes microtubules to combat cancer. Despite past challenges, it

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Parturient Paralysis.

The Journal of comparative medicine and veterinary archives·2022
Same author

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.

Clinical pharmacology and therapeutics·2015
Same author

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2001
Same author

Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate in 0.9% sodium chloride injection.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2001
Same author

Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

A continuous-improvement approach for reducing the number of chemotherapy-related medication errors.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2001
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Paclitaxel is a novel antineoplastic agent.
  • Its clinical development faced challenges including scarcity, extraction difficulties, formulation issues, and hypersensitivity reactions.
  • Paclitaxel was recently approved for treatment-refractory ovarian cancer.

Purpose of the Study:

  • To summarize the pharmacology and clinical development of paclitaxel.
  • To outline its approved indications and ongoing clinical investigations.
  • To discuss efforts in increasing taxane analog availability.

Main Methods:

  • Review of paclitaxel's mechanism of action involving tubulin polymerization and microtubule stabilization.
  • Analysis of clinical data regarding efficacy, adverse effects, and dosing.

Related Experiment Videos

  • Examination of ongoing research for new applications and alternative sourcing.

    • Main Results:

    • Paclitaxel exhibits cytotoxicity by stabilizing microtubules.
    • Major adverse effects include myelosuppression, mucositis, and dose-related neurotoxicity.
    • Approved for refractory ovarian cancer, with ongoing studies for initial therapy and other malignancies.

    Conclusions:

    • Paclitaxel is an effective antineoplastic agent with a defined toxicity profile.
    • Further research is exploring its broader application in oncology.
    • Alternative sourcing strategies are being developed to enhance taxane availability.